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or not), and to estimate the impact of treatment cost. METHODS: We conducted a 
population-based observational cohort study of patients who presented for PEP in 
BCB in 2007 and 2008. Data collected included details of HIV exposure, drug regi-
mens and treatment cost. RESULTS: In 2008, 498 patients came in emergencies for 
a possible HIV exposure (17% more than 2007). The majority were male (61.4%) 
and presented after sexual exposure (60.6%). Mean age was 31.4/0.4 years. Only 
in 47.6%, ARVs were prescribed (tri-therapy in all cases) according to guidelines. 
Median time to receive PEP after hospital admission was 1h07. On average, 19/1 
days of treatment were dispensed per patient. For 2008, the total acquisition cost of 
PEP drugs was a13,8580 (1.1% of the total HIV treatment budget, 14.6% compared 
to 2007) equivalent of a171,785 in a societal point of view. Mean cost per patient 
was a585/38. Without discriminating prescription of PEP, the total cost would have 
been a291,243. Since French recommendations (march 2008) authorizing TDFFTC 
(Truvada®) in ﬁrst intention as AZT3TC (Combivir®), associated with lopinavir/r, 
we observed a change in PEP prescription compared to 2007, which explained at 
72.5% the cost’s increase observed. CONCLUSIONS: The review of cost-effectiveness 
suggests that PEP may be cost-effective only in certain population subgroups. In our 
hospital only targeted patients at high-risk received PEP according to guidelines. The 
cost difference between TDFFTC and AZT3TC highlighted here will enable us to 
begin a revision of local recommendations.
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Patients at risk of developing invasive candida infection can be diagnosed early, using 
new rapid technologies. Accelerated diagnose allows earlier shift in antifungal therapy 
for patients insufﬁciently treated by ﬁrst choice of antifungal medicine. OBJECTIVES: 
To analyze the economic consequences for the Intensive Care Units (ICU) of a faster 
diagnose and when indicated earlier shift in therapy using PCR compared with a tra-
ditional blood culture. METHODS: A decision-tree based costing model was designed 
to compare the two approaches to diagnosing (blood culture alone versus PCR plus 
blood culture). The model compares the costs of the diagnostic methods, costs of 
medicines as well as costs of LOS at the ICU for the two alternatives. The data for 
the costing model was based on data for a half year of patients at Copenhagen Uni-
versity Hospital in 2008 having an invasive candida infection (n  10), and all costs 
were from a Danish perspective. RESULTS: All patients in risk of developing invasive 
candida infection are treated with ﬂuconazol until diagnosed positive. Based on a 
national surveillance of patterns of resistance up to 35% of the patients will be shifted 
to an echinocandin after diagnose. A faster diagnose and early shift in therapy with 
echinocandin will imply in average an extra medicine costs between a 254–267. 
However, at the same time LOS at ICU will in average be reduced by 1.4 days, which 
will result in savings as high as a4859. Diagnose with PCR and use of echinocandin 
for the 35% of the relevant patients could therefore result in savings up to a4605 per 
patient. CONCLUSIONS: Rapid diagnose with PCR and early shift in therapy to 
echinocandin is cost-effective. However, different budgets (including the DRG 
payment) at the hospital are affected, why silo thinking might be a barrier, when 
deciding upon the cost-effective strategy.
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OBJECTIVES: Streptococcus pneumoniae is one of the most frequent causes of 
invasive(IPD) and non-invasive infections(Non-IPD), causing 1.6 million deaths 
worldwide in 2002. PCV-7 provides a reliable protection for children a2 years old.
We aimed to perform an economic evaluation of three doses plus a booster (31) 
compared to an abbreviated scheme (21) and with non-vaccination. METHODS: We 
developed a Markov model of ten annual cycles to estimate the costs and outcomes 
for a birth cohort of 1,955,284. Another model was designed to estimate the herd 
immunity effects during a year in the non-vaccinated population,98% coverage rate 
was assumed.Efﬁcacy data from published sources was adjusted by serotype coverage 
and all costs reﬂect local practice.Direct medical costs included the immunization 
program, medical attention of IPD/Non-IPD and sequels of meningitis.All costs (dis-
counted with an annual rate of 5%) were calculated in 2008 Mexican Pesos (MXP) 
and then expressed in US dollars (USD) using an exchange rate of 1 USD to 11.14 
MXP (exchange rate by the time the study was performed). Disability-adjusted life 
years (DALY) were estimated following standard methods and assumptions. RESULTS: 
For the vaccinated cohort, the full scheme is a cost-saving intervention, costing US$10 
million less than the abbreviate scheme and US$51 million less than non-vaccination. 
Adding the herd immunity beneﬁts, overall savings increases to US$17.40 million 
(beneﬁt : cost ratio 1.08) compared to (21) scheme and reaches US$121.19 million 
(beneﬁt : cost ratio 1.54) compared with non-vaccination.The DALY averted with the 
full scheme are 35,988 and 172,813 compared to (21) scheme and non-vaccination, 
respectively. CONCLUSIONS: The full scheme (31) of PCV-7 had lower costs and 
better health outcomes when compared to both an abbreviated scheme (21) and 
non-vaccination, even if herd immunity is not taken into account.Although the 31 
schedule is dominant the 21 schedule remains highly cost effective vs. no vaccination 
at all.
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OBJECTIVES: To investigate the resource use and cost of rotavirus gastroenteritis 
(RVGE) in children aged 5 years presenting to primary care in four European coun-
tries, Italy, Spain, the Czech Republic and Poland. METHODS: This observational, 
prospective study collected data from children aged 5 years presenting to primary 
care (general practitioners and paediatricians) with acute gastroenteritis (deﬁned as 
diarrhoea for 14 days) and a positive test for rotavirus. Severity of RVGE was 
assessed using the Vesikari score. Parents completed a cost questionnaire at a follow-
up visit or phone call 14 days after the episode, recording information on: direct 
medical costs (physician visits and contacts including the initial visit, use of medica-
tion, rehydration solutions and nutritional products); direct non-medical costs (trans-
port, supervision/carer costs, other costs); and indirect costs (days lost at work or 
school/daycare). All costs were recorded in 2006 Euros. RESULTS: Cost data were 
available for 502 children, of whom 126 were in Italy, 217 in Spain, 87 in Poland 
and 72 in the Czech Republic. A total of 65% of the children (n  326) were aged 0–24 
months, 52% (n  263) were male, and 82% (n  410) were rated as moderate/severe 
using the Vesikari score. The mean total societal cost per child was a170.6 in Italy, 
a169.7 in Spain, a44.0 in Poland and a37.6 in the Czech Republic. The share of the 
total societal cost borne by the family was highest in Italy (57.5%), compared with 
55.0% in Poland, 48.3% in Spain and 35.9% in the Czech Republic. CONCLU-
SIONS: Paediatric RVGE presenting to primary care is associated with substantial 
direct and indirect costs, a high proportion of which are borne by families. These data 
will be valuable in economic evaluations of paediatric rotavirus vaccination. Acknowl-
edgements to the SPRIK investigators, VIVA Spanish investigators, José Baldó, Nadia 
Meyer and Montse Soriano-Gabarró
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OBJECTIVES: To investigate the cost of acute gastroenteritis (AGE) in children aged 
3 years attending daycare centres in France. METHODS: This observational, pro-
spective study was conducted at 15 daycare centres in Paris, France. Children were 
eligible for the study if they had an episode of AGE (deﬁned as q3 loose stools within 
24 hours, lasting for 14 days) before their third birthday. Parents completed a cost 
questionnaire for the affected child and household contacts (a person spending at least 
50% of nights in the same home) who also experienced AGE in the 14 days before 
or after onset of gastroenteritis in the affected child. Information on direct medical 
costs (general practitioner or paediatrician visits and phone consultations, hospitalisa-
tions, emergency room visits, and use of medication, rehydration solutions and nutri-
tional products); direct non-medical costs (transport, supervision/carer costs, other 
costs); and indirect costs (lost workdays) was recorded in 2006 Euros. RESULTS: 
Cost data were available for 71 episodes in 62 subjects (57 children attending daycare 
and 5 household contacts) of the 113 subjects in the study. Of the children attending 
daycare, 47% were male and 86% were aged a24 months. Most episodes (67%) were 
scored as mild/moderate using the Vesikari scale and 21% tested positive for rotavirus. 
The mean societal cost was a253.6 (SD 409.3) per episode, of which direct medical 
costs accounted for a93.2 (37%), non-medical direct costs a16.0 (6%) and indirect 
costs a144.4 (57%). Most of the total cost (63%) was borne by families, reﬂecting 
the importance of indirect costs. Rotavirus-positive episodes (n  15) had higher mean 
total costs than rotavirus-negative episodes (n  51), at a437.7 (SD a527.1) and a172.0 
(SD a304.0) per episode, respectively. CONCLUSIONS: These data show the impor-
tance of indirect costs borne by families, and provide useful information for economic 
evaluations of paediatric rotavirus vaccination.
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OBJECTIVES: In China, 93 million people are chronically infected with hepatitis B 
virus, causing around 19,300 deaths annually. However, detailed costs of treating 
CHB have not been well studied, particularly within the growing urban areas. This 
study aimed to assess the annual direct medical costs for the management of CHB in 
three cities in China. METHODS: Medical claims of 8,954 urban CHB patients from 
Beijing, Nanjing, and Qingdao between January 2006 and December 2007 were ran-
domly reviewed. Demographics; inpatient and outpatient costs; type of medications, 
including antiviral and Traditional Chinese Medicine [TCM], were all recorded and 
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stratiﬁed by the stage of disease. RESULTS: Annual outpatient costs per patient were 
694; 877; and US$1409 for Qingdao, Nanjing, and Beijing, respectively. Among out-
patient expenses, western medications formed the bulk of these costs in Qingdao 
(58.9%) and Beijing (62.9%), but a lesser amount in Nanjing (46.9%). The use of 
antivirals is 20% in Nanjing and 37% in Qingdao of total western medications. TCM 
prescriptions for CHB varied across these different cities with the greatest usage in 
Nanjing (20.8%). For hospitalized patients, annual costs per patient were 1893; 2101, 
and US$2622 in Nanjing, Qingdao, and Beijing, respectively. The costs increased 
progressively in patients with compensated liver disease, (US$1983) decompensated 
liver disease (US$2802) and hepatocellular cancer (US$3019), respectively. Patients 
contributed around 50% towards outpatient costs and 30% towards inpatient care. 
CONCLUSIONS: CHB exerts a signiﬁcant health and ﬁnancial burden which progres-
sively increases as patients progress from early to late stages of the disease. While 
antivirals are associated with a reduction in disease progression, their use remains 
relatively low in urban areas in China. Further work is required to determine whether 
an early treatment with effective CHB medications can reduce the overall ﬁnancial 
burden within China.
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OBJECTIVES: Outbreaks of inﬂuenza often incur a substantial burden in terms of 
health care utilization, health care costs and societal costs. The aim of this analysis 
was to identify gaps in available data related to the economic burden of inﬂuenza in 
children in the UK, Germany, Italy, Spain, France, Sweden, The Netherlands, Finland, 
and Austria. METHODS: A structured literature search (1970-March 2009) involving 
PubMed, EMBASE, and the Cochrane Library formed the basis of the gap analysis. 
Articles were excluded if not related to inﬂuenza and not reporting resource use, cost, 
absenteeism or utility data in a country of interest for a group a18 years. A total of 
171 articles were short-listed for full-text review, and data extracted from 43. 
RESULTS: Available published data suggests a signiﬁcant burden of inﬂuenza in chil-
dren. Most studies reporting health care utilization (31 of 32) focused on hospitaliza-
tion, clinician visits, and prescription of antibiotics, antipyretics, or analgesics. 
Regarding cost burden of inﬂuenza, the number of studies speciﬁcally related to the 
pediatric population was small, and rarely included a breakdown by age group and 
disease severity. Absenteeism data focused on missed days at day care/school or 
parental lost work days. Little information was reported on household contacts or on 
reductions in productivity. Studies reporting impact on quality of life were very 
limited. Burden information is fragmented and incomplete. Only for Italy, France, and 
Spain are data available from multiple studies speciﬁc to a pediatric cohort. CONCLU-
SIONS: Existing information suggests a signiﬁcant burden of inﬂuenza in children. 
Burden information across reviewed EU countries is incomplete and fragmented. A 
multinational data collection initiative providing a complete and age-stratiﬁed picture 
of the burden of inﬂuenza in children appears warranted.
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OBJECTIVES: Anti-venom is the only speciﬁc treatment to prevent neurological dis-
orders, amputation and death in snakebite envenoming, categorized as neglected 
tropical disease by WHO. Majority of victims are young and economically productive. 
Hence, the economic impact of their disability is considerable. We reviewed the burden 
and cost of snakebite envenoming: its incidence, morbidity and mortality rates, and 
the access to anti-venom treatment. METHODS: The information was retrieved from 
1985–2009 from MEDLINE, Google Scholar and WHO website with search terms 
including “snakebite”, “antivenom”, “cost of antivenom” and “snakebite morbidity 
and mortality”. RESULTS: Snakebite as a tropical disease causes considerable morbid-
ity and mortality worldwide with global annual estimates for 2007 ranging from 
1,200,000–5,500,000 for snakebite incidence to 42,1000–1,841,000 and 20,000–
94,000 for envenoming and deaths respectively. South Asia (121,000) has the highest 
number of envenoming followed by Southeast Asia (111,000) and east-Sub-Saharan 
Africa (43,000). The price of anti-venom has typically risen by 10 fold over the last 
20 years. For example, the costs to Australian hospitals of CSL polyvalent and taipan 
antivenoms were A$1833 and A$1577 in 2003 as compared to A$300 and A$245 in 
1985, respectively. The number of anti-venom vials increases with severity (upto 5, 
10 and 20 for mild, moderate and severe cases respectively) thereby increasing cost 
of treatment. Inadequate anti-venom supply further exaggerates this problem as the 
current annual need amounts to 10,000,000 vials. Incidence is higher in rural areas, 
where incomes are generally lower. In Nepal, out-of-pocket expenses (US$69) equal 
several months of income as most people have a daily incomes of 1–2 US$, besides 
15 days of working incapacity period. CONCLUSIONS: The excessive cost and 
inadequate supply of anti-venom renders it inaccessible to most people in developing 
countries. Appropriate measures should be taken to prevent the clinical and economic 
impact of this neglected disease.
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OBJECTIVES: Despite a signiﬁcant decrease over the last 20 years, the prevalence of 
hepatitis B remains high in Portugal (an estimated 36,000 cases in 2002). Hepatitis B 
represents a relevant public health issue due to its dramatic consequences when it turns 
chronic, namely the associated risk of cirrhosis and hepatocellular carcinoma. The aim 
of this study was to estimate annual cost of disease states associated with chronic 
hepatitis B (CHB) from the perspective of Portuguese NHS. METHODS: We estimated 
the resource use to treat CHB and its disease states, namely Compensated Cirrhosis 
(CC), Decompensated Cirrhosis (DC), Hepatocellular Carcinoma (HCC) and Liver 
Transplantation follow-up (LT).A panel of 8 specialists from Portuguese NHS hospi-
tals were surveyed using a modiﬁed Delphi technique. Data were collected for outpa-
tient visits, laboratory tests, diagnostic and therapeutic procedures, drugs (excluding 
antivirals) and hospitalisations. RESULTS: The resource use for all categories increases 
with severity of disease. Estimated average annual costs are a1,125 for CHB, a1,761 
for CC, a18,278 for DC and a26,388 for HCC. Cost for LT procedure within Portu-
guese DRG is estimated at a100,785, while average post-LT costs are estimated at 
a30,540 and a24,780 for the ﬁrst and subsequent years, respectively. Costs for CHB 
and CC are mainly due to outpatient visits and serology tests. By contrast, inpatient 
days are the main driver of costs for DC (79%), HCC (50%) and post-LT in the ﬁrst 
year after treatment (71%). Drugs represent the second major component of costs for 
HCC (18%), and post-LT in the ﬁrst (23%) and second (72%) year, related to immu-
nosuppressants and hepatitis B immunoglobulin respectively. CONCLUSIONS: Our 
study shows that annual costs of managing CHB disease states are high and increase 
substantially with disease severity. Both economic arguments and public health ones 
point to the necessity to control CHB infection and its progression.
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OBJECTIVES: Poor adherence is a serious issue in the management of patients with 
chronic hepatitis C (CHC) owing to the difﬁculty of treatment with pegylated inter-
feron/ribavirin (Peg-IFN/RBV). Future small molecule treatments may obviate difﬁcul-
ties of Peg-IFN/RBV therapy. We analyzed cohorts of CHC patients treated with 
Peg-IFN/RBV to quantify the impact of medication adherence on health care costs 
over 4 years follow-up. METHODS: A retrospective claims analysis was performed 
from January 1, 2001 through December 31, 2007 using the Medstat MarketScan 
database. Inclusion criteria: 1) CHC patients greater than 18 years; 2) who initiated 
Peg-IFN/RBV treatment in 2002 (index); and 3) continued for greater than 24 weeks 
from index. Continuous enrollment from 6 months prior to index (baseline) to 48 
weeks after index (follow-up) was required. Patients were excluded if they had a 
diagnosis of HIV or HBV. Adherence was deﬁned by medication possession ratio 
(MPR), days with Peg-IFN/RBV divided by 336 days or 48 weeks. Overall Medical 
and Pharmacy costs were compared between adherent (MPR q 80%) versus non-
adherent patients (MPR  80%), controlling for age, gender and baseline costs. 
RESULTS: A total of 1173 patients met study inclusion criteria (adherent, n  319; 
non-adherent, n  854). The majority of patients were male (64.5%); the mean age 
was 47 years. Univariate analysis revealed that Overall Medical, ER, Inpatient and 
Outpatient Hospitalizations, and Pharmacy costs were signiﬁcantly greater (P a 0.05) 
in non-adherent compared to adherent patients. Multivariate analysis conﬁrmed these 
results (difference in mean; 95% CI) for Overall Medical ($10,006; 1530–18,482) and 
Outpatient Hospitalization ($3,024; 553–5,494) costs. CONCLUSIONS: Medication 
non-adherence to Peg-IFN/RBV treatment was associated with greater health care 
costs. These results may be due to decreased Sustained Viral Response associated with 
low adherence. Treatment with future small molecules may potentially improve adher-
ence and reduce costs.
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OBJECTIVES: To quantify and compare the impact of using different methods for 
measuring indirect cost on the total disease cost in the economic assessment of 7-valent 
pneumococcal conjugate vaccines (PCV-7) versus pneumococcal non-typeable Hae-
mophilus inﬂuenzae protein-D conjugate vaccine (PHiD-CV) in Germany.   METHODS: 
Five different ways of using the human capital (HCM) and friction cost method (FCM) 
for estimating indirect cost have been incorporated into an age-compartmental, one-
year cross-sectional, vaccine steady-state, population-based model assessing the 
